About 30 percent of all non-Hodgkin lymphoma diagnoses in the United States are DLBCL. Although it is an aggressive cancer that can spread quickly, it is treatable. These can be symptoms of many ...

Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid neoplasm. Three subtypes have been identified by gene-expression studies; germinal center (GC) DLBCL, non-GC DLBCL, and ...

These investigators used SEER data to compare the outcomes of transformed indolent non-Hodgkin lymphomas with de novo DLBCL at a population level, a situation for which little data exist.

Managing R/R-transformed DLBCL remains a challenge, as affected patients have an approximate 27% chance of 4-year event-free survival and a 39% chance of overall survival. 2 Atezolizumab is a ...

The addition of brentuximab vedotin to lenalidomide and rituximab improved survival for certain patients with DLBCL. A similar percentage of patients in each arm experienced treatment-emergent ...

While the grading scales used were different so no direct ... which is approved for DLBCL and another form of non-Hodgkin’s lymphoma called primary mediastinal large B-cell lymphoma (PMBCL ...

A study has shown that bortezomib can enhance the activity of doxorubicin-based chemotherapy for the treatment of activated B-cell-like (ABC) diffuse large B-cell lymphoma (DLBCL). This ...

Cytokine Release Syndrome, or CRS, of Grade 1 or 2 according to ASTCT grading was observed in 34. ... for the treatment of relapsed or refractory DLBCL after two or more lines of systemic therapy.